Kim Soo-Young, Park Yeon-Joon, Yu Jin Kyung, Kim Yeong Sic
Department of Laboratory Medicine, College of Medicine, The Catholic University of Korea, St. Vincent's Hospital, Suwon, Korea.
Korean J Lab Med. 2011 Oct;31(4):279-81. doi: 10.3343/kjlm.2011.31.4.279. Epub 2011 Oct 3.
The aminoglycoside 6'-N-acetyltransferases of type Ib (aac(6')-Ib) gene confers resistance to amikacin, tobramycin, kanamycin, and netilmicin but not gentamicin. However, some isolates harboring this gene show reduced susceptibility to amikacin. The European Committee on Antimicrobial Susceptibility Testing (EUCAST) recommends a revision of the phenotypic description for isolates harboring the aac(6')-Ib gene. In this study, we determined the aminoglycoside susceptibility profiles of 58 AAC(6')-Ib-producing Enterobacter cloacae isolates. On the basis of the CLSI and EUCAST breakpoints, a large proportion (84.5% and 55.2%, respectively) of these 58 isolates were found to be susceptible to amikacin. However, among the isolates that were shown to be anikacin-susceptible according to the CLSI and EUCAST breakpoints, only 30.6% and 18.8% isolates, respectively, could be considered to have intermediate resistance on the basis of the EUCAST expert rules. Further studies should be conducted to determine the aminoglycoside susceptibility profiles of aac(6')-Ib-harboring isolates from various geographic regions and to monitor the therapeutic efficacy of amikacin in infections caused by these isolates.
I型b类氨基糖苷6'-N-乙酰基转移酶(aac(6')-Ib)基因赋予对阿米卡星、妥布霉素、卡那霉素和奈替米星的耐药性,但对庆大霉素无耐药性。然而,一些携带该基因的分离株对阿米卡星的敏感性降低。欧洲抗菌药物敏感性试验委员会(EUCAST)建议修订对携带aac(6')-Ib基因分离株的表型描述。在本研究中,我们测定了58株产AAC(6')-Ib的阴沟肠杆菌分离株的氨基糖苷类药物敏感性谱。根据CLSI和EUCAST的断点,这58株分离株中很大一部分(分别为84.5%和55.2%)对阿米卡星敏感。然而,在根据CLSI和EUCAST断点显示对阿米卡星敏感的分离株中,根据EUCAST专家规则,分别只有30.6%和18.8%的分离株可被认为具有中介耐药性。应进一步开展研究,以确定来自不同地理区域的携带aac(6')-Ib的分离株的氨基糖苷类药物敏感性谱,并监测阿米卡星对这些分离株引起感染的治疗效果。